Skip to Content
Merck
CN
  • Role of hypoxia-inducible factor 1, α subunit and cAMP-response element binding protein 1 in synergistic release of interleukin 8 by prostaglandin E2 and nickel in lung fibroblasts.

Role of hypoxia-inducible factor 1, α subunit and cAMP-response element binding protein 1 in synergistic release of interleukin 8 by prostaglandin E2 and nickel in lung fibroblasts.

American journal of respiratory cell and molecular biology (2013-03-26)
Kelly A Brant, James P Fabisiak
ABSTRACT

Numerous epidemiological studies have linked exposure to particulate matter (PM) air pollution with acute respiratory infection and chronic respiratory and cardiovascular diseases. We have previously shown that soluble nickel (Ni), a common component of PM, alters the release of CXC chemokines from cultured human lung fibroblasts (HLF) in response to microbial stimuli via a pathway dependent on disrupted prostaglandin (PG)E2 signaling. The current study sought to identify the molecular events underlying Ni-induced alterations in PGE2 signaling and its effects on IL-8 production. PGE2 synergistically enhances Ni-induced IL-8 release from HLF in a concentration-dependent manner. The effects of PGE2 were mimicked by butaprost and PGE1-alcohol and inhibited with antagonists AH6809 and L-161,982, indicating PGE2 signals via PGE2 receptors 2 and 4. PGE2 and forskolin stimulated cAMP, but it was only in the presence of Ni-induced hypoxia-inducible factor 1, α subunit (HIF1A) that these agents stimulated IL-8 release. The Ni-induced HIF1A DNA binding was enhanced by PGE2 and mediated, in part, by activation of p38 MAPK. Negation of cAMP-response element binding protein 1 or HIF1A using short interfering RNA blocked the synergistic interactions between Ni and PGE2. The results of the current study provide novel information on the ability of atmospheric hypoxia-mimetic metals to disrupt the release of immune-modulating chemokines by HLF in response to PGE2. Moreover, in the presence of HIF1A, cAMP-mediated signaling pathways may be altered to exacerbate inflammatory-like processes in lung tissue, imparting a susceptibility of PM-exposed populations to adverse respiratory health effects.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Prostaglandin E2, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Prostaglandin E2, ≥93% (HPLC), synthetic
Sigma-Aldrich
Nickel(II) sulfate, 99.99% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ReagentPlus®, powder or crystals
Sigma-Aldrich
Nickel(II) sulfate hexahydrate, ACS reagent, ≥98%
Supelco
Nickel(II) sulfate hexahydrate, ≥99.99% trace metals basis
Sigma-Aldrich
Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Prostaglandin E1, powder, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Prostaglandin E1, ≥98% (HPLC), synthetic
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, 99.999% trace metals basis
Sigma-Aldrich
Nickel(II) sulfate hexa-/ heptahydrate, DIN 50970 H, ≥20.6% Ni and Co basis
Sigma-Aldrich
AH6809, ≥98%, crystalline solid or supercooled liquid
Sigma-Aldrich
(R)-Butaprost, ≥98% (HPLC)
Dinoprostone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Nickel(II) sulfate heptahydrate, purum p.a., crystallized, ≥99.0% (KT)
Alprostadil, European Pharmacopoeia (EP) Reference Standard